Grace Therapeutics Inc. (GRCE), a late-stage biopharmaceutical company, on Thursday announced financial results for the fiscal year ending March 31, 2026, and provided updates on the NDA resubmission for GTx-104 in treating aneurysmal subarachnoid hemorrhages.